331943-04-5 Usage
Description
N-De(4-sulfonaMidophenyl)-N'-(4-sulfonaMidophenyl) Celecoxib, also known as Celecoxib EP Impurity B, is an isomeric impurity of Celecoxib (C251000) derived from the pharmaceutical compound Celecoxib. It is characterized by its off-white solid appearance and possesses selective inhibitory activity against human cyclooxygenase-2 (COX-2), a key enzyme involved in inflammation and pain.
Uses
Used in Pharmaceutical Industry:
N-De(4-sulfonaMidophenyl)-N'-(4-sulfonaMidophenyl) Celecoxib is used as an isomeric impurity in the pharmaceutical industry for Celecoxib (C251000). Its selective inhibitory activity against human COX-2 makes it a valuable compound for research and development in the field of pain management and anti-inflammatory drugs.
Used in Research and Development:
In the research and development sector, N-De(4-sulfonaMidophenyl)-N'-(4-sulfonaMidophenyl) Celecoxib is utilized for studying the effects and mechanisms of COX-2 inhibition. This helps in understanding the potential therapeutic applications and side effects associated with Celecoxib and its related compounds.
Used in Quality Control:
N-De(4-sulfonaMidophenyl)-N'-(4-sulfonaMidophenyl) Celecoxib is also used in the quality control process of Celecoxib manufacturing. As an isomeric impurity, it is essential to monitor and control its presence in the final product to ensure the safety, efficacy, and consistency of Celecoxib as a pharmaceutical drug.
Check Digit Verification of cas no
The CAS Registry Mumber 331943-04-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,1,9,4 and 3 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 331943-04:
(8*3)+(7*3)+(6*1)+(5*9)+(4*4)+(3*3)+(2*0)+(1*4)=125
125 % 10 = 5
So 331943-04-5 is a valid CAS Registry Number.
331943-04-5Relevant articles and documents
Synthesis and Spectral Characterization of Impurities of a COX-2 Selective Drug, Celecoxib
Lee, Young Hee,Vishwanath, Manjunatha,Lanka, Srinu,Lee, Eunhwa,Park, Yongbin,Lee, Sunhwan,Sim, Jaeuk,Lee, Seohoo,Lee, Kiho,Viji, Mayavan,Lee, Heesoon,Jung, Jae-Kyung
, p. 479 - 480 (2019)
-
Solvent- and transition metal catalyst-dependent regioselectivity in the [3+2]cyclocondensation of trifluoromethyl-α,β-ynones with hydrazines: Switchable access to 3- and 5-trifluoromethylpyrazoles
Hsieh, Min-Tsang,Kuo, Sheng-Chu,Lin, Hui-Chang
, p. 683 - 689 (2015/03/18)
The regioselectivity of the [3+2]cyclocondensation of trifluoromethyl-α,β-ynones with hydrazines can be readily tuned to preferentially afford either 3- or 5-trifluoromethylpyrazoles through variation of the reaction conditions. Under catalysis with copper(II) acetate (2.0 mol%), cyclocondensation proceeded smoothly to yield 3-trifluoromethylpyrazoles with high regioselectivity. In contrast, when the reaction was conducted in dimethyl sulfoxide under catalyst-free conditions, the formation of 5-trifluoromethylpyrazoles was predominantly observed.
An improved and scalable process for celecoxib: A selective cyclooxygenase-2 inhibitor
Reddy, Anumula Raghupathi,Sampath, Alla,Goverdhan, Gilla,Yakambaram, Bojja,Mukkanti, Kagga,Reddy, Padi Pratap
experimental part, p. 98 - 101 (2010/04/22)
An improved, scalable and commercially viable process is developed for an active pharmaceutical ingredient, celecoxib.
